CN111773212A - Application of daphnetin - Google Patents
Application of daphnetin Download PDFInfo
- Publication number
- CN111773212A CN111773212A CN202010815902.6A CN202010815902A CN111773212A CN 111773212 A CN111773212 A CN 111773212A CN 202010815902 A CN202010815902 A CN 202010815902A CN 111773212 A CN111773212 A CN 111773212A
- Authority
- CN
- China
- Prior art keywords
- daphnetin
- atopic dermatitis
- skin
- mice
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ATEFPOUAMCWAQS-UHFFFAOYSA-N 7,8-dihydroxycoumarin Chemical compound C1=CC(=O)OC2=C(O)C(O)=CC=C21 ATEFPOUAMCWAQS-UHFFFAOYSA-N 0.000 title claims abstract description 76
- YBGKGTOOPNQOKH-UHFFFAOYSA-N daphnetin Natural products OC1=CC=CC2=C1OC(=O)C=C2O YBGKGTOOPNQOKH-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 51
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 49
- 210000003630 histaminocyte Anatomy 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 16
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract description 9
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 9
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 9
- 206010039509 Scab Diseases 0.000 claims abstract description 5
- 206010040882 skin lesion Diseases 0.000 claims description 23
- 231100000444 skin lesion Toxicity 0.000 claims description 23
- 210000003491 skin Anatomy 0.000 claims description 17
- 230000008595 infiltration Effects 0.000 claims description 14
- 238000001764 infiltration Methods 0.000 claims description 14
- 210000004969 inflammatory cell Anatomy 0.000 claims description 10
- 206010000496 acne Diseases 0.000 claims description 8
- 206010040867 Skin hypertrophy Diseases 0.000 claims description 6
- 210000004209 hair Anatomy 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 206010058679 Skin oedema Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 22
- 238000002474 experimental method Methods 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 8
- 108090000695 Cytokines Proteins 0.000 abstract description 5
- 102000004127 Cytokines Human genes 0.000 abstract description 5
- 230000037380 skin damage Effects 0.000 abstract description 4
- 206010033733 Papule Diseases 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229950003937 tolonium Drugs 0.000 description 3
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000722953 Akebia Species 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960003657 dexamethasone acetate Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000349 Acanthosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 241000742679 Coprosma repens Species 0.000 description 1
- 241001163443 Daphne giraldii Species 0.000 description 1
- 241000046691 Daphne odora Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241001534930 Thymelaeaceae Species 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
The invention discloses an application of daphnetin. Experiments prove that the daphnetin can improve papules, crusts and the like at skin damage parts of mice with atopic dermatitis models, reduce the number of mast cells at the skin damage parts, and reduce the levels of IgE, IL-4, IL-13 and IL-6 in the blood serum of the mice with the atopic dermatitis models. Daphnetin may exert a therapeutic effect on atopic dermatitis by regulating the expression of mast cells and Th2 type cytokines to inhibit inflammation. Daphnetin has application prospect in the medicines for treating and preventing atopic dermatitis.
Description
Technical Field
The invention belongs to the technical field of medicines, relates to an application of daphnetin, and particularly relates to an application of daphnetin in medicines for treating and preventing atopic dermatitis.
Background
Atopic Dermatitis (AD) is a common chronic, recurrent, inflammatory skin disease. The disease occurs in all ages, with children being the most common, and about 10% to 20% and 1% to 3% of adults all over the world suffer from AD. Epidemiological studies find that the prevalence of AD in most countries of the world, particularly economically developed countries, has increased substantially over the last 30 years, with the prevalence of children reaching even as high as 10% -20% in europe and america; in China, the prevalence of atopic dermatitis has also been increasing for 20 years. The disease is generally clinically divided into 3 stages: infancy, childhood, adolescence and adulthood. After the age of 45, the patients with the disease are rare, and the patients who are stubborn can be cured by the age of 50-60. It is clinically characterized by extensive erythema, papules, desquamation, and persistent itching and dry skin, and patients often have a family history of "atopy". Frequent scratching results in thickening of the skin, lichenification and often immediate (type i) allergic reactions. Most of AD patients are adolescents and children, and currently, antihistamine drugs, hormone drugs, antibiotics and the like are mostly adopted, so that the side effect is large, and a plurality of adverse factors are generated on growth and development after long-term use, so that the search for medicines with small toxic and side effects and definite curative effect is imperative.
The traditional Chinese medicine considers that the skin disease is not only the pathological changes of the skin, but also the result of the general immune dysfunction, so the treatment is carried out by improving the general state and differentiating the symptoms. TCM gives play to the advantages of internal treatment, and usually has better effect when modified according to the disease condition. However, the clinical traditional Chinese medicine compound for treating AD of infants and children usually contains akebia stem, which is not suitable for long-term use and large-scale application due to the fact that akebia stem has bitter and cold properties to release heart and kidney qi and can cause renal failure, so that the application of traditional Chinese medicine in treating AD is limited.
Daphnetin (Daphnetin, Dap.) is Daphnetin A extracted from daphne giraldii of Thymelaeaceae. Changbai Daphne odora is bitter and pungent in taste and warm in nature and enters heart, liver and lung meridians; it excels in relaxing muscles and tendons, activating collateral flow, promoting blood circulation, and removing blood stasis. Daphnetin is odorless and tasteless, is white or off-white powder, is slightly soluble in methanol, is slightly soluble in ethanol, and is insoluble in water. The chemical name is 7, 8-dihydroxycoumarin with the molecular formula of C9H6O4Structural formula is
。
In the research process, the inventor finds that the daphnetin has the effect of treating and preventing atopic dermatitis.
Disclosure of Invention
The invention aims to provide application of daphnetin in medicines for treating and preventing atopic dermatitis.
The purpose of the invention is realized as follows:
daphnetin can protect the skin of atopic dermatitis patients, and promote the growth of part of new hair at skin lesion, and improve pimple and incrustation, and has the following structural formula:
daphnetin can protect atopic dermatitis patients from skin thickening, edema, inflammatory cell infiltration, etc.
Daphnetin inhibits mast cell number in skin lesions.
Daphnetin decreases IgE levels.
Daphnetin inhibits the expression of Th2 type cytokines IL-4, IL-6, IL-13.
Atopic dermatitis is atopic dermatitis, eczema, neurodermatitis or seborrheic dermatitis.
The dosage form of the medicine is oral dosage form or external dosage form.
The daphnetin dose is 3 times daily, 0.5-2g each time.
The dose of daphnetin is 3 times daily, 1g each time.
The invention has the advantages that:
1. the invention provides experimental research to prove that daphnetin can protect the skin of an atopic dermatitis model mouse, so that part of new hair grows from skin damage, and pimples and scabs are improved.
2. The invention provides application of daphnetin, namely application of daphnetin in preparing a medicament for treating atopic dermatitis, and the daphnetin can protect daphnetin of an atopic dermatitis model mouse and can effectively inhibit the conditions of skin thickening, edema, inflammatory cell infiltration and the like of the atopic dermatitis model mouse. The daphnetin has certain inhibitory effect on the number of mast cells at skin lesions after acting on atopic dermatitis model mice. Daphnetin can reduce IgE level and inhibit expression of Th2 type cytokines IL-4, IL-6 and IL-13.
Drawings
FIG. 1 is the appearance of skin lesions in mice;
FIG. 2 is the observation of pathological morphology of HE staining of dorsal skin lesion tissues of AD mice (200 ×);
FIG. 3 shows mast cell infiltration (200X) in skin lesion tissues of AD mice;
FIG. 4 shows the effect of daphnetin on the IgE expression level in the serum of AD mice;
note: # #: p < 0.01; *: p < 0.05; **: p < 0.01; ns: no significant difference exists;
FIG. 5 shows the effect of daphnetin on the expression level of cytokines in the serum of AD mice;
note: # # # # #: p < 0.0001; # #: p < 0.01; *: p < 0.05; **: p < 0.01; ***: p < 0.005;
***: p < 0.001; ns: there was no significant difference.
Detailed Description
The present invention is further illustrated but not limited in any way by the following examples, and any modifications made thereto are intended to fall within the scope of the present invention.
Application of daphnetin in preparing medicine for treating and preventing atopic dermatitis is provided.
Daphnetin can protect the skin of atopic dermatitis patients, and promote the growth of part of new hair at skin lesion, and improve pimple and incrustation, and has the following structural formula:
daphnetin can protect atopic dermatitis patients from skin thickening, edema, inflammatory cell infiltration, etc.
Daphnetin inhibits mast cell number in skin lesions.
Daphnetin decreases IgE levels.
Daphnetin inhibits the expression of Th2 type cytokines IL-4, IL-6, IL-13.
Atopic dermatitis is atopic dermatitis, eczema, neurodermatitis or seborrheic dermatitis.
The dosage form of the medicine is oral dosage form or external dosage form.
The daphnetin dose is 3 times daily, 0.5-2g each time.
The dose of daphnetin is 3 times daily, 1g each time.
Example 1:
1 materials of the experiment
1.1 animals
48 female BALB/c mice, SPF grade 6-8 weeks old, weight (20. + -.2) g, purchased from Schleksider laboratory animals Ltd, Hunan, animal license number [ SCXK (Hunan) 2016-. Adaptive feeding for 1 week, and feeding in clean animal room with no specific pathogen, air flow, temperature (23 + -2) ° C, humidity (55 + -5)%, light darkness per 12 hr as a circulation, and free food and water acquisition of mouse.
1.2 drugs and Primary Agents
Daphnetin, shanghai source leaf biotechnology limited; dexamethasone acetate, Zhejiang Xianju pharmaceutical products, batch number: 170512, respectively; 2, 4-dinitrochlorobenzene, Dodbett reagent, Inc., production batch No.: Z0016B 5; acetone, yunnan pharmaceutical industry limited company in the development area of the Yunnan Yanglin industry, production lot number: 20160325, respectively; olive oil, Shandong Lu Hua group Co., Ltd, production batch number: 20180803, respectively; sodium carboxymethylcellulose, shinyleaf fine chemical research institute in Tianjin, production lot number: 50116; elisa kit, dear, production lot number: 1218202.
1.3 Main experimental equipment and equipment
Full-wavelength multifunctional enzyme-labeling instrument, Beijie science and technology, model: plus 384; ultra low temperature refrigerator at-80 ℃, Thermo Forma company, usa, model: forma 902; low temperature high speed centrifuge, Eppendorf company, germany, model number: 5810R; electronic analytical balance, aohaus instruments ltd, model number: AR224 CN.
2 method of experiment
2.1 model replication, grouping and administration
BALB/c mice were adapted for 1 week and then used in the experiment, and were randomly divided into a blank control group, a model control group, a positive control group (dexamethasone acetate 2 mg/kg), daphnetin low, medium and high dose groups (25, 50, 100 mg/kg), 8 mice per group. 1 day before the experiment, all mice had their backs depilated (2 cm. times.2 cm) with electric clippers plus depilatory cream, exposing the skin; on the 1 st and 2 nd days of the experiment, except for the blank control group, the mice in other groups were smeared with 1% 2, 4-Dinitrochlorobenzene (DNCB) solution prepared by using an acetone-olive oil mixed solution as a solvent on the skin with depilated back, 100 uL of the solution was used once, no treatment was performed on the 3 rd to 6 th days, and on the 7 th day, 1 0.3% DNCB solution was smeared once every 1 day, 70 uL of the solution was used once, until the 28 th day. The unhaired skin on the back of the mice in the blank control group was applied with the acetone-olive oil mixed solution only, and the application time and volume were consistent with those of the model building group. The corresponding drugs were administered by gavage for 1 time/day and 28 days continuously from the 1 st day of the experiment.
2.2 sample selection and processing
After the last administration, fasting is carried out for 12 h, the abdominal aorta blood is collected from the anesthetized animals, the spleen and the thymus are dissected, the skin lesion tissue at the back molding position is cut into 2 parts, one part is placed in a refrigerator at the temperature of minus 80 ℃, and the other part is placed in 10% neutral formalin solution.
2.3 measurement index and method
(1) General observations in mice
Weighing and recording the weight of the mice every day; one day after each molding, the mice were observed for skin lesions on the back, including erythema (hemorrhage), erythema (pimple), exfoliation (scratch), scaling (dryness), etc., and recorded by photographing.
(2) General histopathological observations
Taking out the skin lesion tissue fixed in 10% neutral formalin solution, dehydrating, waxing, embedding, slicing, etc. to prepare pathological sections, and then carrying out HE staining.
(3) Mast cell infiltration number of skin lesion tissue
Paraffin section, dewaxing, Toluidine Blue (TB) staining, washing, drying, mounting, observing infiltration condition of Mast Cells (MC) in dermis of mouse skin tissue under a microscope, randomly selecting 8 visual fields in each group, photographing, mounting, and counting infiltration quantity of Mast cells.
(4) Serum total IgE and Th2 type cytokine expression
The Elisa method is used for measuring the content of total IgE and cytokines IL-6, IL-4 and IL-13 in serum.
2.4 statistical treatment
The data obtained were statistically analyzed using Graphpad prism 8.0.2 software, with data expressed as mean ± standard deviation, and using one-way anova and t-test analysis, values of P <0.05 indicating that the difference was statistically significant.
3 results of the experiment
3.1 Effect of daphnetin on skin lesion tissue in AD model mice
3.1.1 appearance of skin lesions in mice
The skin of the blank control group mouse is normal, and the tissue structure is basically normal; the skin of the mouse in the model control group can be changed by skin damage such as erythema, dryness, scale, pimple and incrustation; after 28 days of continuous administration, the skin of the back of the positive control group mice is smoother, and only a very small amount of scales can be seen; the daphnetin high-dose mice had a small amount of scales on the back, no obvious erythema, and some new hairs were grown on the skin lesions on the back of the individual animals at the end of the experiment, and the pimples and scabs of the middle-low dose mice were improved to some extent, and the results are shown in fig. 1.
3.1.2 general histopathology of mouse skin lesions
HE staining shows that the skin structure of the mice in the blank control group is complete and normal in shape, and no vasodilation and inflammatory cell infiltration are seen in the dermis; the skin structure of a tested region on the back of a mouse in a model control group is seriously damaged, hyperkeratosis is caused, the thick and thick spinous layer is obviously accompanied with focal spongiform edema, dermal blood vessels are dilated and congested and accompanied with a large amount of inflammatory cell infiltration, and the hair follicle structure is reduced; compared with a model control group, the positive control group mice have clear structures of all layers of the epidermis, the thickening of the epidermis is obviously reduced, the dermis does not have vasodilatation, inflammatory cells are obviously reduced compared with the model group, and hair follicle structures are obviously increased; the skin cornification degree of mice in the high and medium dose daphnetin groups is reduced, the acanthosis and focal spongiform edema are obviously reduced, the infiltration of inflammatory cells in the dermis is obviously reduced, the hair follicle structure is obviously increased, and the specific result is shown in figure 2. The daphnetin is suggested to be capable of effectively inhibiting the conditions of skin thickening, edema, inflammatory cell infiltration and the like of an AD model mouse.
3.2 Effect of daphnetin on mast cell infiltration in skin lesions of AD model mice
Toluidine blue staining showed only a small number of mast cells visible in the blank control; more mast cells were visible in the model control compared to the blank control; compared with a model control group, a small amount of mast cells can be seen at the skin lesion of the mice in the positive control group, and the number is obviously reduced; the number of mast cells at skin lesions of the AD model mice can be obviously reduced by high, medium and low daphnetin doses, wherein the number of the mast cells in a daphnetin high dose group is slightly higher than that in a positive control group, and the specific figure is shown in figure 3. The daphnetin has a certain inhibition effect on the number of mast cells at skin lesions after acting on AD model mice.
3.3 Effect of daphnetin on serum Total IgE and cytokine levels in AD model mice
Compared with a blank control group, the contents of total IgE and IL-4, IL-6 and IL-13 in the serum of the mouse in the model control group are obviously increased; compared with the model control group, each dose of daphnetin can obviously reduce the serum total IgE level and the contents of IL-4, IL-6 and IL-13, and the results are shown in a figure 4 and a figure 5; it is suggested that daphnetin can reduce IgE levels and inhibit the expression of Th2 type cytokines.
4. Conclusion
In the mouse AD model test, the dosage of daphnetin is 1 time per day, and the dosage is 25, 50 and 100 mg/kg each time. The dosage is converted into 1 time per day (calculated by adult weight 60 kg), 1.5, 3, 6 g each time. In consideration of taking, the recommended dose is 0.5-2g per 3 times a day. The most common dosage is 1g each time 3 times daily.
The daphnetin provided by the invention can protect the skin of an AD model mouse, so that part of new hair grows from the skin lesion, and pimples and scabs are improved. Daphnetin can effectively inhibit skin thickening, edema, inflammatory cell infiltration and the like of AD model mice. The daphnetin has a certain inhibiting effect on the number of mast cells at skin lesions after acting on AD model mice. Daphnetin can reduce IgE level and inhibit expression of Th2 type cytokines IL-4, IL-6 and IL-13.
Claims (10)
1. The application of daphnetin is characterized in that the daphnetin is applied to preparing a medicine for treating and/or preventing atopic dermatitis, and the structural formula of the daphnetin is as follows:
。
2. the use of daphnetin according to claim 1, wherein daphnetin is capable of protecting the skin of atopic dermatitis patients by growing new hair from skin lesions and improving pimples and scabs.
3. The use of daphnetin according to claim 1, wherein daphnetin is capable of protecting skin thickening, edema and inflammatory cell infiltration in atopic dermatitis patients.
4. The use of daphnetin according to claim 1, wherein daphnetin inhibits mast cell number in lesions.
5. The use of daphnetin according to claim 1, wherein daphnetin reduces IgE levels.
6. The use of daphnetin according to claim 1, wherein daphnetin inhibits the expression of the Th2 type cytokines IL-4, IL-6, IL-13.
7. Daphnetin for use according to claim 1, wherein the atopic dermatitis is eczema, neurodermatitis or seborrheic dermatitis.
8. The use of daphnetin according to claim 1, wherein daphnetin is formulated for oral or topical administration.
9. The daphnetin application according to claim 1, wherein the daphnetin is applied in an amount of 0.5-2g per time and 3 times a day.
10. Daphnetin for use according to claim 1, wherein the daphnetin is administered in an amount of 1g 3 times a day.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010815902.6A CN111773212A (en) | 2020-08-14 | 2020-08-14 | Application of daphnetin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010815902.6A CN111773212A (en) | 2020-08-14 | 2020-08-14 | Application of daphnetin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111773212A true CN111773212A (en) | 2020-10-16 |
Family
ID=72762033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010815902.6A Pending CN111773212A (en) | 2020-08-14 | 2020-08-14 | Application of daphnetin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111773212A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101039689A (en) * | 2004-06-12 | 2007-09-19 | 西格纳姆生物科学公司 | Topical compositions and methods for epithelial-related conditions |
| WO2009096695A2 (en) * | 2008-01-28 | 2009-08-06 | Alphacryptec Co., Ltd. | Cosmetic composition for alleviating pruritus or inflammation containing daphnetin |
| WO2015102642A1 (en) * | 2014-01-03 | 2015-07-09 | Scioderm, Inc. | Allantoin compositions for treating inflammatory skin conditions |
| CN105566269A (en) * | 2015-03-27 | 2016-05-11 | 北京大学 | Preparation and pharmacological effects of coumarin derivative and application of coumarin derivative to treatment on pruritus |
-
2020
- 2020-08-14 CN CN202010815902.6A patent/CN111773212A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101039689A (en) * | 2004-06-12 | 2007-09-19 | 西格纳姆生物科学公司 | Topical compositions and methods for epithelial-related conditions |
| WO2009096695A2 (en) * | 2008-01-28 | 2009-08-06 | Alphacryptec Co., Ltd. | Cosmetic composition for alleviating pruritus or inflammation containing daphnetin |
| WO2015102642A1 (en) * | 2014-01-03 | 2015-07-09 | Scioderm, Inc. | Allantoin compositions for treating inflammatory skin conditions |
| CN105566269A (en) * | 2015-03-27 | 2016-05-11 | 北京大学 | Preparation and pharmacological effects of coumarin derivative and application of coumarin derivative to treatment on pruritus |
Non-Patent Citations (4)
| Title |
|---|
| BEOM-GEUN JO，等: "A new flavonoid from Stellera chamaejasme L., stechamone, alleviated 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in a murine model", 《INT IMMUNOPHARMACOL》 * |
| 何荣安，等: "瑞香素对TNF-α刺激的HaCaT角质形成细胞炎症因子表达的影响", 《世界最新医学信息文摘》 * |
| 张祎，等: "民族药抗特应性皮炎活性研究进展", 《中华中医药杂志》 * |
| 武雪，等: "HPLC同时测定瑞香狼毒中瑞香素、伞形花内酯和东莨菪内酯的含量", 《中国现代应用药学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101313660B1 (en) | Therapeutic effects cream for anti-atopic | |
| Lee et al. | Triticum aestivum sprout extract attenuates 2, 4‑dinitrochlorobenzene‑induced atopic dermatitis‑like skin lesions in mice and the expression of chemokines in human keratinocytes | |
| JP6542275B2 (en) | Composition for preventing or treating allergic skin diseases which comprises GPCR 19 agonist as an active ingredient {Composition for preventing or treating allergic dermatitis comprising GPCR 19 agonist as an active ingredient} | |
| WO2008061447A1 (en) | A medicine for treating eczema and process of ointment thereof | |
| KR100483539B1 (en) | Composition for preventing or treating atopic dermatitis and process for preparation thereof | |
| CN102716380B (en) | Compound acne-removal cream and production method thereof | |
| CN111773212A (en) | Application of daphnetin | |
| CN115227774A (en) | Use of Phalaenopsis amabilis extract for preparing composition for inhibiting formation of saccharification final product | |
| KR101690012B1 (en) | Composition for Treating Dermatitis Comprising Extract of Weeping Fern | |
| CN103638204B (en) | A kind of Chinese medicine composition for the treatment of eczema | |
| WO2022077276A1 (en) | Application of combination of nicotinamide mononucleotide and lactobacillus fermentum in preparation of formulation for relieving skin photoaging | |
| CN108853276B (en) | Compound cream for moistening dryness and relieving itching and preparation method thereof | |
| Yuan et al. | NLRP3 neuroinflammatory intervention of Mahuang-Lianqiao-Chixiaodou decoction for mental disorders in atopic dermatitis mice | |
| CN110624081A (en) | Traditional Chinese medicine composition for treating goiter and preparation method thereof | |
| CN110917186A (en) | Application of icaritin in preparation of medicine for treating bronchial asthma | |
| CN113975323B (en) | Traditional Chinese medicine composition for treating atopic dermatitis and preparation method and application thereof | |
| CN114028476B (en) | External traditional Chinese medicine composition for treating atopic dermatitis and preparation method and application thereof | |
| KR102382067B1 (en) | Composition for treating atopic dermatitis comprising Complex extract of Schizonepeta Tenuifolia Briq. and Alpinia Oxyphylla Miq. as an active ingredient | |
| CN114767810B (en) | Traditional Chinese medicine composition for treating acute lung injury as well as preparation method and application thereof | |
| CN101683427B (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN114452354B (en) | Traditional Chinese medicine composition for wounds, extract and application thereof | |
| CN111166796B (en) | Compound preparation for treating skin inflammation and preparation method thereof | |
| CN108186709B (en) | Application of sedum aizoon in preparing medicine for treating or preventing alcohol-induced hyperlipidemia and/or alcoholic liver disease | |
| CN111096987A (en) | Application of silver leaf tree fruit in preparing medicine for treating ulcerative colitis | |
| CN116570656A (en) | External-use anti-atopic dermatitis three-herb itching-relieving formula essential oil, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201016 |
|
| RJ01 | Rejection of invention patent application after publication |